ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
121.802,06
-0,19%
S&P 500
5.291,34
0,15%
US Dollar vs BRL
5,2895
0,74%
Bitcoin
70.610,88
2,63%
Brent Oil
77,10
-1,33%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. IO Biotech Inc (IOBT)

  7. IO Biotech Inc (IOBT) Notícias

IOBT

IO Biotech (IOBT)

IO Biotech Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:IOBT
DataHoraFonteTítuloCódigoCompanhia
23/05/202409:30GlobeNewswire Inc.IO Biotech to Present at Jefferies Global Healthcare ConferenceNASDAQ:IOBTIO Biotech Inc
14/05/202409:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOBTIO Biotech Inc
14/05/202409:13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IOBTIO Biotech Inc
14/05/202408:55GlobeNewswire Inc.IO Biotech Reports First Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:IOBTIO Biotech Inc
24/04/202417:30GlobeNewswire Inc.IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:IOBTIO Biotech Inc
15/04/202409:30GlobeNewswire Inc.IO Biotech Expands Senior Leadership Team to Progress Commercialization ReadinessNASDAQ:IOBTIO Biotech Inc
09/04/202413:00GlobeNewswire Inc.IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103NASDAQ:IOBTIO Biotech Inc
05/04/202409:30GlobeNewswire Inc.IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business OfficerNASDAQ:IOBTIO Biotech Inc
11/03/202417:56Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IOBTIO Biotech Inc
06/03/202418:11GlobeNewswire Inc.IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:IOBTIO Biotech Inc
05/03/202419:17Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:IOBTIO Biotech Inc
05/03/202418:40GlobeNewswire Inc.IO Biotech Announces 2023 Fourth-Quarter and Year-End ResultsNASDAQ:IOBTIO Biotech Inc
26/02/202418:05GlobeNewswire Inc.IO Biotech to Present at 44th Annual Cowen Health Care ConferenceNASDAQ:IOBTIO Biotech Inc
21/12/202310:30GlobeNewswire Inc.IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket TrialNASDAQ:IOBTIO Biotech Inc
24/11/202319:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IOBTIO Biotech Inc
13/11/202310:12GlobeNewswire Inc.IO Biotech Announces 2023 Third Quarter ResultsNASDAQ:IOBTIO Biotech Inc
13/11/202310:00GlobeNewswire Inc.IO Biotech Appoints Helen Collins, MD, to its Board of DirectorsNASDAQ:IOBTIO Biotech Inc
10/11/202310:00GlobeNewswire Inc.IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced MelanomaNASDAQ:IOBTIO Biotech Inc
08/11/202318:30GlobeNewswire Inc.IO Biotech Announces Participation in Upcoming Investor ConferencesNASDAQ:IOBTIO Biotech Inc
01/11/202309:30GlobeNewswire Inc.IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNASDAQ:IOBTIO Biotech Inc
23/10/202302:00GlobeNewswire Inc.Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European SocieNASDAQ:IOBTIO Biotech Inc
03/10/202317:30GlobeNewswire Inc.IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNASDAQ:IOBTIO Biotech Inc
12/09/202317:06Edgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]NASDAQ:IOBTIO Biotech Inc
12/09/202309:05GlobeNewswire Inc.IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung CancerNASDAQ:IOBTIO Biotech Inc
11/09/202301:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IOBTIO Biotech Inc
07/09/202311:36Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:IOBTIO Biotech Inc
30/08/202317:16Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:IOBTIO Biotech Inc
21/08/202316:40Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IOBTIO Biotech Inc
11/08/202309:30GlobeNewswire Inc.IO Biotech Announces 2023 Second Quarter ResultsNASDAQ:IOBTIO Biotech Inc
11/08/202309:05GlobeNewswire Inc.IO Biotech Appoints Heidi Hunter to its Board of DirectorsNASDAQ:IOBTIO Biotech Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:IOBT

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
BHIA3
Grupo Casas Bahia ON
BOV
GFSA3
GAFISA ON
BOV
AZEV4
AZEVEDO PN
BOV
AMER3
Americanas ON
BOV
OIBR3
OI ON
BOV
RCSL3
RECRUSUL ON
BOV
IFCM3
Infracommerce Caxaas ON
BOV
COGN3
COGNA ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
CEAB3
C&A ON
BOV
RRRP3
3R Petroleum Oleo E Gas ... ON
BOV
SEQL3
Sequoia Logistica e Tran... ON
BOV
HAGA3
HAGA ON
BOV
GOLL4
GOL PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados